109,317 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 109,317 shares of the company's stock, valued at approximately $1,447,000.

Other hedge funds have also bought and sold shares of the company. QRG Capital Management Inc. raised its holdings in Takeda Pharmaceutical by 16.8% during the 4th quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock valued at $4,364,000 after buying an additional 47,490 shares during the period. Versant Capital Management Inc purchased a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at $26,000. Russell Investments Group Ltd. boosted its stake in shares of Takeda Pharmaceutical by 48.6% during the fourth quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock valued at $600,000 after purchasing an additional 14,831 shares in the last quarter. US Bancorp DE increased its holdings in Takeda Pharmaceutical by 21.2% during the fourth quarter. US Bancorp DE now owns 124,332 shares of the company's stock valued at $1,646,000 after buying an additional 21,744 shares during the period. Finally, Blue Trust Inc. raised its stake in Takeda Pharmaceutical by 27.0% in the fourth quarter. Blue Trust Inc. now owns 14,430 shares of the company's stock worth $205,000 after buying an additional 3,071 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Down 5.2 %

Takeda Pharmaceutical stock traded down $0.78 during trading hours on Thursday, reaching $14.28. The stock had a trading volume of 633,835 shares, compared to its average volume of 1,928,456. Takeda Pharmaceutical Company Limited has a 52 week low of $12.57 and a 52 week high of $15.43. The company has a market cap of $45.44 billion, a price-to-earnings ratio of 35.70, a PEG ratio of 0.24 and a beta of 0.26. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The business's 50 day moving average price is $14.90 and its 200-day moving average price is $13.99.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Sell-side analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.